Usage: Donepezil hydrochloride tablets are indicated for treating Alzheimer's disease dementia, with proven efficacy in patients across mild, moderate, and severe stages.
Usage: KISUNLA™ is indicated for the treatment of Alzheimer's disease, specifically for patients with mild cognitive impairment or mild dementia, where clinical trials initiated treatment.
Usage: LEQEMBI is indicated for treating Alzheimer’s disease in patients with mild cognitive impairment or mild dementia. Treatment should begin in this early stage, as demonstrated in clinical trials.
Usage: NAMZARIC is indicated for treating moderate to severe Alzheimer's-type dementia in patients who are stabilized on a daily dose of 10 mg of donepezil hydrochloride.
Usage: TAUVID is indicated for PET imaging of the brain to estimate tau neurofibrillary tangles density in adult patients with cognitive impairment being evaluated for Alzheimer's disease. It is not indicated for chronic traumatic encephalopathy evaluation.